Company intelligence / Profile preview

Pulmotect

Houston, Texas, United Statespulmotect.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Phase I/2a clinical trials demonstrated PUL-042 was well tolerated in healthy individuals and subjects with COPD. Two exploratory phase 2 trials demonstrated anti-viral activity and proof of clinical concept. Phase 2 studies are planned to assess effectiveness in preventing respiratory complications in immunocompromised cancer patients.[1][2]

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Inhaled therapeutic
Industry: Biotech

Drug pipeline

2 assets

PUL-042

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pulmotect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmotect.

Explore the full profile